science
FDA Commissioner Defends Rejection of Two Drugs
The FDA commissioner defended recent drug rejections in a CNBC interview, citing adherence to scientific reviews amid reports of agency turmoil. Criticism includes a high-profile denial of a melanoma treatment from Replimune and pressure from President Trump over vape approvals. The commissioner emphasized avoiding past mistakes like overruling scientists on certain drugs.
prnewswire.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The U.S. Food and Drug Administration's commissioner defended the agency's recent drug approval decisions in an interview, pushing back against mounting criticism over rejections, including a melanoma drug from Replimune. Reports from Bloomberg News highlighted paranoia, turmoil, and backlash within the agency, while a Wall Street Journal opinion piece questioned the commissioner's impact on President Donald Trump's administration.
In the CNBC interview aired Tuesday, the commissioner stated that multiple independent teams had reviewed the Replimune case and reached the same conclusion. The commissioner emphasized standing by FDA scientists and noted that overruling them has led to disasters in the past.
Examples cited included the approval of an Alzheimer's drug called Aduhelm and the clearance of a Covid-19 vaccine booster for young, healthy children. The commissioner added that the agency has not engaged in corrupt deals. This adds to the pressure on the agency amid a wave of backlash over its decisions.
Replimune representatives have argued that the FDA treated the company unfairly in rejecting its melanoma drug candidate. The commissioner countered that the decision was based on thorough reviews and not influenced by external pleas. The Wall Street Journal editorial specifically pointed to the Replimune rejection as a key example, marking it as one of several pieces urging approval.
The commissioner referenced a news conference at FDA headquarters in Silver Spring, Maryland, on April 28, 2026, as part of the ongoing discussions. The agency maintains that its processes prioritize public interest over industry pressures. Criticism has intensified with reports detailing internal challenges at the FDA, but the commissioner affirmed confidence in the review teams.
